Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00386087 · ClinicalTrials.gov registry record · Phase 2
Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy
A Phase 2 study of Breast Neoplasms, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT00386087 is a Phase 2 study of Breast Neoplasms that has completed, run by Eli Lilly and Company. The registered enrollment target is 41 participants, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (93% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT00386087, a Phase 2 study of Breast Neoplasms, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.
Conditions Studied
Interventions
- DRUG Enzastaurin Hydrochloride
Study Locations (4)
Indiana
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Indianapolis
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - South Bend
Delaware
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Newark
Massachusetts
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2006-11 |
| Est. Completion | 2007-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00386087
The ClinicalTrials.gov registry entry for NCT00386087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (93% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which Enzastaurin Hydrochloride is the first listed.
NCT00386087 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Indiana, Delaware, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00386087 about?
NCT00386087 is a clinical study titled "Enzastaurin For Breast Cancer Patients Who Previously Received an Anthracycline and a Taxane Chemotherapy". The purpose of this study is to determine the effectiveness of enzastaurin in the treatment of patients with metastatic breast cancer.
What is the current status of trial NCT00386087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2006-11. Estimated completion is 2007-09.
What conditions does trial NCT00386087 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT00386087?
The interventions under investigation include: Enzastaurin Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00386087?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00386087 being conducted?
This trial has 4 study locations across Delaware, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
-
Tirzepatide Weight Loss for MRD+ Early Breast Cancer
RECRUITING · Phase 2
-
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
RECRUITING · Phase 2
-
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
RECRUITING · Phase 2
-
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.